Sign in

CIK 0001438533

  • Large accelerated filer

Travere Therapeutics, Inc.

Sign in to watch
Ticker
TVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
CA
Entity type
Operating
EIN
262383102
Phone
+1 888-969-7879
Business address
3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
Former names
Retrophin, Inc., Desert Gateway, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$79,812,468
in 11 filings, $79.8M under 10b5-1 plans

Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-01-31 Dube Eric M CHIEF EXECUTIVE OFFICER Grant or award 10b5-1 +130,000 481,239
2025-01-31 Dube Eric M CHIEF EXECUTIVE OFFICER Grant or award · Employee stock option (right to buy) 10b5-1 +260,000 260,000
2025-01-31 Inrig Jula CHIEF MEDICAL OFFICER Grant or award 10b5-1 +30,000 89,443
2025-01-31 Inrig Jula CHIEF MEDICAL OFFICER Grant or award · Employee stock option (right to buy) 10b5-1 +100,000 100,000
2025-01-31 Heerma Peter CHIEF COMMERCIAL OFFICER Grant or award +21,500 127,874
2025-01-31 Heerma Peter CHIEF COMMERCIAL OFFICER Grant or award · Employee stock option (right to buy) +58,000 58,000
2025-01-31 Cline Christopher R. CHIEF FINANCIAL OFFICER Grant or award +21,500 95,230
2025-01-31 Cline Christopher R. CHIEF FINANCIAL OFFICER Grant or award · Employee stock option (right to buy) +58,000 58,000
2025-01-31 Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Grant or award +13,000 67,002
2025-01-31 Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Grant or award · Employee stock option (right to buy) +26,000 26,000
2025-01-23 Baynes Roy D. Director Option exercise 10b5-1 +16,000 $17.50 $280K 47,000
2025-01-23 Baynes Roy D. Director Sale 10b5-1 −16,000 $20.00 $320K 31,000
2025-01-23 Baynes Roy D. Director Option exercise · Stock option (right to buy) 10b5-1 −16,000 0
2025-01-22 ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Sale 10b5-1 −2,437 $19.46 $47K 83,170
2025-01-22 Dube Eric M CHIEF EXECUTIVE OFFICER Sale 10b5-1 −10,736 $19.46 $209K 351,239
2025-01-22 REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Sale 10b5-1 −2,437 $19.46 $47K 76,933
2025-01-22 Heerma Peter CHIEF COMMERCIAL OFFICER Sale −1,584 $18.94 $30K 106,374
2025-01-22 Cline Christopher R. CHIEF FINANCIAL OFFICER Sale −865 $18.94 $16K 73,730
2025-01-22 Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Sale −925 $18.94 $18K 54,002
2025-01-06 Inrig Jula CHIEF MEDICAL OFFICER Sale 10b5-1 −440 $18.76 $8K 59,443

Page 21 of 51 · 1,020 trades